Isomalto oligosaccharide sulfate inhibits tumor growth and metastasis of hepatocellular carcinoma in nude mice
Autor: | Jia Fan, Wei Wei Li, Lu Wang, Zhong Hua Tao, Jin Liang Wan, Lin Guo, Wei Zhong Wu, Zhao-You Tang, Hui-Chuan Sun, Chun Li Xiao |
---|---|
Jazyk: | angličtina |
Předmět: |
Male
endocrine system Cancer Research Carcinoma Hepatocellular Maximum Tolerated Dose proliferation Mice Nude Oligosaccharides Antineoplastic Agents Apoptosis Biology lcsh:RC254-282 Flow cytometry Mice In vivo Cell Movement Cell Line Tumor medicine Cell Adhesion Genetics metastasis Animals Humans Cell adhesion Protein kinase B Mice Inbred BALB C medicine.diagnostic_test Cell growth Gene Expression Profiling Cell Cycle Liver Neoplasms hepatocellular carcinoma Hep G2 Cells Cell cycle lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Molecular biology Xenograft Model Antitumor Assays digestive system diseases Gene Expression Regulation Neoplastic Oncology Cell culture Isomalto oligosaccharide sulfate Research Article Signal Transduction |
Zdroj: | BMC Cancer BMC Cancer, Vol 11, Iss 1, p 150 (2011) |
ISSN: | 1471-2407 |
DOI: | 10.1186/1471-2407-11-150 |
Popis: | Background Hepatocellular carcinoma (HCC) usually has a dismal prognosis because of its limited response to current pharmacotherapy and high metastatic rate. Sulfated oligosaccharide has been confirmed as having potent antitumor activities against solid tumors. Here, we explored the preclinical effects and molecular mechanisms of isomalto oligosaccharide sulfate (IMOS), another novel sulfated oligosaccharide, in HCC cell lines and a xenograft model. Methods The effects of IMOS on HCC proliferation, apoptosis, adhesion, migration, and invasiveness in vitro were assessed by cell counting, flow cytometry, adhesion, wound healing, and transwell assays, respectively. The roles of IMOS on HCC growth and metastasis in xenograft models were evaluated by tumor volumes and fluorescent signals. Total and phosphorylated protein levels of AKT, ERK, and JNK as well as total levels of c-MET were detected by Western blotting. IMOS-regulated genes were screened by quantitative reverse-transcription PCR (qRT-PCR) array in HCCLM3-red fluorescent protein (RFP) xenograft tissues and then confirmed by qRT-PCR in HepG2 and Hep3B cells. Results IMOS markedly inhibited cell proliferation and induced cell apoptosis of HCCLM3, HepG2, and Bel-7402 cells and also significantly suppressed cell adhesion, migration, and invasion of HCCLM3 in vitro. At doses of 60 and 90 mg/kg/d, IMOS displayed robust inhibitory effects on HCC growth and metastasis without obvious side effects in vivo. The levels of pERK, tERK, and pJNK as well as c-MET were significantly down-regulated after treatment with 16 mg/mL IMOS. No obvious changes were found in the levels of pAkt, tAkt, and tJNK. Ten differentially expressed genes were screened from HCCLM3-RFP xenograft tissues after treatment with IMOS at a dose of 90 mg/kg/d. Similar gene expression profiles were confirmed in HepG2 and Hep3B cells after treatment with 16 mg/mL IMOS. Conclusions IMOS is a potential anti-HCC candidate through inhibition of ERK and JNK signaling independent of p53 and worth studying further in patients with HCC, especially at advanced stages. |
Databáze: | OpenAIRE |
Externí odkaz: |